Table 3.
Demographic and clinical data of the study vitiligo patients with and without autoimmune and autoinflammatory disease (n = 294)
| Variable n (%), median (min-max) |
Autoimmune and autoinflammatory diseases | P | |
|---|---|---|---|
| Without (n = 214) |
With (n = 80) |
||
| Age, years | 35 (3–86) | 36.50 (8–78) | < 0.001* |
|
< 18 18–39 40–59 60–79 ≥ 80 |
29 (13.6) 111 (51.9) 64 (29.9) 9 (4.2) 1 (0.5) |
6 (7.5) 42 (52.5) 24 (30.0) 8 (10.0) - |
0.235 |
| Sex | |||
|
Male Female |
108 (50.5) 106 (49.5) |
25 (31.3) 55 (68.8) |
0.003* |
| Disease duration | 8 (0.10–54) | 11.50 (0.30–50) | 0.001* |
| Age at vitiligo onset | 24 (1–84) | 20.50 (2–75) | 0.331 |
| Course of the disease | |||
|
Stationary Regressive Progressive |
50 (23.4) 14 (6.5) 150 (70.1) |
17 (21.3) 7 (8.8) 56 (70) |
0.774 |
| Affected BSA, % | |||
|
1–25 26–50 51–75 76–100 |
90 (42.1) 98 (45.8) 15 (7) 11 (5.1) |
44 (55) 33 (41.3) 1 (1.3) 2 (2.5) |
0.076 |
| Distribution | |||
|
Face or body Face and body |
192 (89.7) 22 (10.3) |
76 (95) 4 (5) |
0.175 |
| Laterality | |||
|
Unilateral/midline Bilateral |
170 (79.4) 44 (20.6) |
71 (88.8) 9 (11.3) |
0.065 |
| Family history of vitiligo | 44 (20.6) | 18 (22.5) | 0.717 |
| Family history of AIIDs | 42 (19.6) | 32 (40) | < 0.001* |
| VIDA | |||
|
+ 4 + 3 + 2 + 1 0 -1 |
39 (18.2) 23 (10.7) 27 (12.6) 57 (26.6) 45 (21.0) 23 (10.7) |
22 (27.5) 9 (11.3) 8 (10.0) 20 (25.0) 12 (15.0) 9 (11.3) |
0.560 |
| Treatment | |||
| No | 95 (44.4) | 46 (57.5) | 0.149 |
| Local | 100 (46.7) | 31 (38.8) | |
| Systemic | 11 (5.1) | 1 (1.3) | |
| Both local and systemic | 8 (3.7) | 2 (2.5) | |
*p < 0.05
AIIDs: autoimmune and autoinflammatory diseases